Advertisement
Advertisement
U.S. markets close in 10 minutes
Advertisement
Advertisement
Advertisement
Advertisement

CytRx Corporation (CYTR)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0894-0.0106 (-10.64%)
As of 01:27PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1000
Open0.0998
Bid0.0000 x 1100
Ask0.0000 x 1000
Day's Range0.0894 - 0.0998
52 Week Range0.0500 - 0.8600
Volume43,879
Avg. Volume65,262
Market Cap4.025M
Beta (5Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)-0.3550
Earnings DateNov 10, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CYTR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CYTRX CORP
    Market Update: CENT, EBAY, PFE, VMC, RKTStocks were mostly higher on Thursday morning amid more signs of moderating inflation. The Labor Department said that its producer price index for final demand fell 0.5% in July, down from a 1.0% increase in June. The reading was the first negative number since April 2020 and below the Reuters consensus forecast, which called for an increase of 0.2%. The Dow rose 0.5%, the S&P rose 0.4%, and the Nasdaq was flat. Crude oil rose 1.5% to $93.50 per barrel, while gold rose $8 to $1806 per ounce.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Business Wire

    CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors

    LOS ANGELES, August 09, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (the "Board").

  • Business Wire

    CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock

    LOS ANGELES, May 19, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 pm Eastern Time on May 20, 2022. The outstanding shares of

  • Business Wire

    CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

    LOS ANGELES, May 17, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. ("KemPharm").

Advertisement
Advertisement